Latest Macroeconomic Environment News

PEXA Group’s third-quarter results align with expectations, driven by Australian growth and UK market headwinds. The company reaffirms its FY25 guidance while navigating ongoing business assessments and regulatory milestones.

Macquarie Bank Limited reported an 18% rise in net profit for FY2025, driven by growth in its retail banking segment despite margin pressures, while its commodities business faced subdued markets. The bank maintained strong capital ratios and advanced its risk and technology frameworks amid regulatory scrutiny.

Vmoto Limited reported a 16% decline in total unit sales for 1Q25, offset by a strong cash position and strategic investments in e-mobility solutions and production capacity.

Amcor has completed its transformative merger with Berry Global ahead of schedule, reporting steady Q3 fiscal 2025 results and setting ambitious synergy targets that promise to reshape its growth trajectory.

Noumi Limited reported a 2.8% revenue increase to $141.4 million in Q3 FY25, buoyed by gains in its Dairy and Nutritionals segment, while managing legacy legal costs and maintaining strong cash flow.

Hydrix Limited reports improved operating performance in Q3 FY25, buoyed by FDA clearance of its Gyder Surgical Hip Navigation system and a reduced cash operating loss, while managing tight liquidity with shareholder support.

Atomos Limited reported a $2.3 million operating cash outflow in Q3 FY25 amid seasonal softness and tariff challenges, while announcing a leadership change and a bold expansion into new product categories beyond its core monitor-recorder business.

Galan Lithium has locked in a binding funding and offtake agreement with Authium Limited for its Hombre Muerto West project, significantly reducing capital and operating costs. The company raised approximately A$13 million via placement and plans further shareholder funding, aiming for lithium chloride production in H1 2026.

BirdDog Technology reported a slight 4.1% decline in Q3 FY25 sales to A$3.6 million while progressing strongly on its next-generation product roadmap and implementing significant cost reductions.

Visionflex Group reported a 46% year-on-year rise in annual recurring revenue to $1.7 million, secured key contracts including a $1 million virtual nursing pilot, and targets operating cash flow positivity in Q4 FY25.

Paradigm Biopharmaceuticals has secured ethics approval and appointed a CRO to launch its global phase 3 trial for injectable Pentosan Polysulfate Sodium in knee osteoarthritis, while initiating a substantial capital raising program.

Pact Group Holdings reports a modest 2.7% revenue increase for Q3 FY25, driven by higher volumes and cost savings, while preparing to refinance debt and review its Asian packaging business.